Office of the Director, National Institutes of Health; Notice of Meeting, 49012-49013 [07-4157]

Download as PDF 49012 Federal Register / Vol. 72, No. 165 / Monday, August 27, 2007 / Notices p.m. and 3 p.m. Time allotted for oral presentations may be limited to 10 minutes. Those desiring to make oral presentations should notify the contact person by October 2, 2007, and submit a brief statement of the general nature of the evidence or arguments they which to present, the names and addresses, phone number, fax, and e-mail of proposed participants, and an indication of the approximate time requested to make their presentation.’’ Dated: August 20, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E7–16892 Filed 8–24–07; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Advisory Commission on Childhood Vaccines; Notice of Meeting Cancellation Notice is hereby given of the cancellation of the Advisory Commission on Childhood Vaccines (ACCV) Meeting, September 7, 2007, 9 a.m. to 5 p.m., Parklawn Building (and via audio conference call), Conference Rooms G & H, 5600 Fishers Lane, Rockville, MD 20857, which was published in the Federal Register on August 15, 2007, 72 FR 45822–45823. Dated: August 21, 2007. Alexandra Huttinger, Acting Director, Division of Policy Review and Coordination. [FR Doc. E7–16868 Filed 8–24–07; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health rmajette on PROD1PC64 with NOTICES National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, VerDate Aug<31>2005 15:56 Aug 24, 2007 Jkt 211001 and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Tissue Engineering and Regenerative Medicine. Date: September 11, 2007. Time: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Charles H. Washabaugh, PhD, Scientific Review Administrator, Review Branch, NIAMS/NIH, 6701 Democracy Blvd., Room 816, Bethesda, MD 20892, 301 451–4838, washabac@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS). Dated: August 15, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–4158 Filed 8–24–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Recombinant DNA Advisory Committee. Date: September 17–18, 2007. Time: September 17, 2007, 8 a.m. to 12 p.m. Agenda: The Recombinant DNA Advisory Committee will review and discuss elected human gene transfer protocols as well as related data management activities. There will also be a discussion about new clinical safety information. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Auditorium, Bethesda, MD 20892. Time: September 17, 2007, 12:30 p.m. to 6 p.m. PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 Agenda: Continued. Place: National Institutes of Health, Building 31, Floor 5C, 31 Center Drive, Conference Room 6, Bethesda, MD 20892. Time: September 18, 207, 8 a.m. to 12 p.m. Agenda: Continued. Place: National Institutes of Health, Building 31, Floor 6C, 31 Center Drive, Conference Room 6, Bethesda, MD 20892. Contact Person: Laurie Lewallen, Advisory Committee Coordinator, Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892–7985, 301–496–9838, lewallla@od.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// www4.od.nih.gov/oba/, where an agenda and any additional information for the meeting will be posted when available. OMB’s ‘‘Mandatory Information Requirements for Federal Assistance Program Announcements’’ (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research General; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from E:\FR\FM\27AUN1.SGM 27AUN1 Federal Register / Vol. 72, No. 165 / Monday, August 27, 2007 / Notices Disadvantaged Backgrounds, National Institutes of Health, HHS) Dated: August 15, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–4157 Filed 8–24–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2007–27813] New MARPOL Annex I Pollution Prevention Regulations; Information and Compliance Policy Coast Guard, DHS. Notice of policy. AGENCY: rmajette on PROD1PC64 with NOTICES ACTION: SUMMARY: This notice informs the public about new requirements of revised Annex I of the International Convention for the Prevention of Pollution from Ships (MARPOL 73/78), their associated entry into force dates, and compliance requirements for U.S. vessels that are subject to the Convention. FOR FURTHER INFORMATION CONTACT: For information concerning this notice, contact Lieutenant Commander Scott Muller, Project Manager, Office of Vessel Activities, Domestic Vessel Division (CG–3PCV–1), telephone 202– 372–1220 or via e-mail at Scott.W.Muller@uscg.mil. If you have questions on viewing material to the DOT Docket Management Facility docket, call Ms. Renee V. Wright, Program Manager, Docket Operations, telephone 202–493–0402. SUPPLEMENTARY INFORMATION: The International Convention for the Prevention of Pollution from Ships (MARPOL 73/78) is the primary international agreement aimed at reducing pollution of the marine environment from a variety of vesselgenerated sources. Annex I to MARPOL 73/78, ‘‘Regulations for the Prevention of Pollution by Oil,’’ contains provisions intended to reduce both intentional and accidental discharges of oil. Annex I was codified into U.S. law by the Act to Prevent Pollution from Ships at Sea 33 U.S.C. Sec. 1901 et seq. and with implementing regulations of 33 CFR parts 151, 155 and 157. The entire annex was revised by adoption of Resolution MEPC.117(52) on October 15, 2004, and entered into force on January 1, 2007. In addition to adding new regulations, MARPOL Annex I was revised to be more userfriendly. It separates, by chapter, the VerDate Aug<31>2005 15:56 Aug 24, 2007 Jkt 211001 49013 requirements for: Survey and certification, machinery spaces of all ships, cargo areas of oil tankers, oil pollution emergency plans, reception facilities, and fixed or floating platforms. Additionally, where applicable, chapters are further divided by subpart concerning construction, equipment and operational requirements. Two new regulations were included in the revision: • Regulation 22 of revised Annex I, ‘‘Pump-room bottom protection,’’ establishes design requirements for pump-room double bottoms on oil tankers of 5,000 tons deadweight and above constructed on or after January 1, 2007. • Regulation 23 of revised Annex I, ‘‘Accidental oil outflow performance,’’ establishes design requirements to protect against oil pollution in the event of grounding or collision for oil tankers with a building contract on or after January 1, 2007 (or delivery on or after January 1, 2010). In addition, on March 24, 2006, IMO adopted Resolution MEPC.141(54) which provided additional amendments that further revised MARPOL Annex I, which will enter into force on August 1, 2007. These amendments include a new regulation 12A: • Regulation 12A of revised Annex I, ‘‘Oil fuel tank protection,’’ establishes design requirements for protectively located fuel tanks for all ships with an aggregate oil fuel capacity of 600 cubic meters (m3) and above with a building contract on or after August 1, 2007 (or delivery on or after August 1, 2010). U.S. vessels required to hold an IOPP Certificate must meet all requirements set out in MARPOL 73/78, including the new requirements, as applicable, established in recent IMO resolutions MEPC.117(52) and MEPC.141(54) discussed above that have come into force. (b) U.S. flagged vessels that are not required to hold an IOPP Certificate: These vessels need not presently comply with the new MARPOL Annex I regulations, adopted by IMO resolutions MEPC.117(52) and MEPC.141(54) above. However, vessel operators are encouraged to comply with these new regulations in light of the Coast Guard’s intention to revise domestic regulations (33 CFR 157 and 155) that will implement IMO resolution MEPC.117(52) and MEPC.141(54). (c) Foreign vessels calling to the U.S. ports or terminals: The Coast Guard will enforce all applicable MARPOL Annex I regulations, including the new regulations adopted by IMO resolutions MEPC.117(52) and MEPC.141(54) discussed above. Reason for Policy Notice As a signatory to the MARPOL 73/78 the U.S. government has an obligation to act in accordance with the convention. This obligation includes implementing and enforcing the new amendments to the convention for both U.S. vessels and foreign flagged vessels operating in U.S. waters. Thus, vessels required to have an International Oil Pollution Prevention (IOPP) certificate by the convention will need to meet the new revised regulations. Because the new revisions affect certain vessels subject to existing U.S. regulations, found at 33 CFR parts 157 and 155, the Coast Guard is developing a proposed rulemaking to harmonize existing U.S. regulations with the new revisions to the convention. In the interim, as a party to MARPOL 73/78, the United States will enforce the new MARPOL Annex I regulations as follows: (a) U.S. flagged vessels that are required to hold an International Oil Pollution Prevention (IOPP) Certificate in accordance with 33 CFR 151.19: All DEPARTMENT OF THE INTERIOR PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 Authority: 33 U.S.C. 1903, 33 U.S.C. 1231, 33 U.S.C. 1321, E.O. 12777, Department of Homeland Security Delegation No. 0170.1. Dated: August 20, 2007. J.G. Lantz, Acting Assistant Commandant for Prevention, U.S. Coast Guard. [FR Doc. E7–16725 Filed 8–24–07; 8:45 am] BILLING CODE 4910–15–P Bureau of Land Management [AZ–933–07, 5410–KD–A507; AZA–33515] Application for Conveyance of Federal Mineral Interests, Pima County, AZ Bureau of Land Management, Interior. ACTION: Notice of application. AGENCY: SUMMARY: The surface owner of the lands described in this notice, aggregating approximately 320.00 acres, has filed an application for the purchase of the federally owned mineral interests in the lands. Publication of this notice temporarily segregates the mineral interest from appropriation under the public land laws, including the mining law. DATES: Interested persons may submit written comments to the Bureau of Land Management (BLM) at the address stated below. Comments must be received by no later than October 11, 2007. E:\FR\FM\27AUN1.SGM 27AUN1

Agencies

[Federal Register Volume 72, Number 165 (Monday, August 27, 2007)]
[Notices]
[Pages 49012-49013]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-4157]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: September 17-18, 2007.
    Time: September 17, 2007, 8 a.m. to 12 p.m.
    Agenda: The Recombinant DNA Advisory Committee will review and 
discuss elected human gene transfer protocols as well as related 
data management activities. There will also be a discussion about 
new clinical safety information.
    Place: National Institutes of Health, Natcher Building, 45 
Center Drive, Auditorium, Bethesda, MD 20892.
    Time: September 17, 2007, 12:30 p.m. to 6 p.m.
    Agenda: Continued.
    Place: National Institutes of Health, Building 31, Floor 5C, 31 
Center Drive, Conference Room 6, Bethesda, MD 20892.
    Time: September 18, 207, 8 a.m. to 12 p.m.
    Agenda: Continued.
    Place: National Institutes of Health, Building 31, Floor 6C, 31 
Center Drive, Conference Room 6, Bethesda, MD 20892.
    Contact Person: Laurie Lewallen, Advisory Committee Coordinator, 
Office of Biotechnology Activities, National Institutes of Health, 
6705 Rockledge Drive, Room 750, Bethesda, MD 20892-7985, 301-496-
9838, lewallla@od.nih.gov.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: https://www4.od.nih.gov/oba/, where an agenda and any 
additional information for the meeting will be posted when 
available.
    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecule techniques could 
be used, it has been determined not be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research General; 93.39, Academic 
Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency 
Syndrome Research Loan Repayment Program; 93.187, Undergraduate 
Scholarship Program for Individuals from

[[Page 49013]]

Disadvantaged Backgrounds, National Institutes of Health, HHS)

    Dated: August 15, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-4157 Filed 8-24-07; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.